Company* |
University/ |
Type Of |
Product Area | Details (Date) |
| | ||||
Aegis Therapeutics |
Albany Medical College |
License agreement |
Aegis got rights to the college's anti-obesity peptide |
Aegis will assess the peptide with its Intravail intranasal delivery technology; terms of the deal were not disclosed (5/16) |
AEterna |
Julius Maximilians University (Germany) |
Collaboration |
Deal to develop tumor vaccines based on attenuated bacterial carriers |
AEterna also acquired rights to immunotherapeutic approaches against cancer and bacterial tumor targeting; terms were not disclosed (4/21) |
Affitech A/S* |
Research Foundation of the Norwegian Radium Hospital |
License agreement |
Affitech got exclusive rights to cancer-specific human antibodies |
Affitech and the hospital have been collaborating in the area, using Affitech's Cell-Based Antibody Selection technology; terms were not disclosed(5/18) |
Andara Life |
Purdue University |
License agreement |
Andara got rights to develop the oscillating field stimulator technology |
The technology is designed to stimulate nerve regeneration, and have applicability in central nervous systems diseases; terms were not disclosed (4/14) |
Arrowhead |
Ludwig Maximilians University (Germany) |
Patent acquisitions |
The patents cover nanosensor technology for use in disease diagnosis |
The portfolio covers techniques for measuring biomolecular interactions by single-molecule-force spectroscopy; it complements Arrowhead's IP (5/19) |
Bionaut |
National Cancer Institute |
Collaboration |
Deal to profile Bionaut cancer compounds that inhibit the ability of tumor cells to survive stress conditions |
They also will work to identify new biomarkers in tumor cells that are affected by Bionaut's lead cancer compounds; terms were not disclosed (5/19) |
Bridge |
National Foundation for Cancer Research |
Collaboration |
They will jointly fund and manage cancer research programs in both the U.S. and Asia |
The goal is to accelerate discovery and development at a lower cost (5/17) |
CellCentric |
Babraham |
License agreement |
CellCentric got rights to epigenetic-related intellectual property generated at Babraham |
CellCentric will use its discovery platform to develop cancer products, and fund specific research at the institute (4/7) |
ChemBridge |
St. Jude Children's Research Hospital Inc. |
Collaboration |
They extended a previously unannounced deal on targets related to anaplastic lymphoma kinase |
They will apply CRL's discovery medicinal chemistry platform to targets from St. Jude cancer research; terms of the deal were not disclosed (5/4) |
Ciphergen |
National Cancer Institute |
Material transfer agreement |
The NCI will evaluate Ciphergen Diagnostics' ProteinChip technology and associated bioinformatics suites |
The NCI's Clinical Proteomics Reference Laboratory will use the technology to study biomarker patterns indicative of ovarian cancer (4/28) |
CODA |
University of California at Irvine |
License agreement |
CODA got rights to Computer Optimized DNA Assembly (CODA) and protein- xpression optimization technology |
The company was formed to commercialize the technology; terms of the deal were not disclosed (4/27) |
Crucell NV |
National Institutes of Health |
License agreement |
Crucell got exclusive rights to patents for use in recombinant vaccines against Ebola virus |
The patents cover vaccine components, such as Ebola antigens and vectors; terms of the deal were not disclosed (3/18) |
Cryptome |
Murdoch Childrens Research Institute (Australia) |
License agreement |
Cryptome got rights to two unique proteins to mine for novel drug candidates |
Cryptome gets all rights to proucts emerging from the deal, terms of which were not disclosed (4/8) |
Cryptome |
Northeastern University |
Agreement |
Cryptome got rights to use the university's technology to identify and isolate low-abundance human proteins |
Cryptome gets rights to drug candidates emerging from the deal, terms of which were not disclosed (4/6) |
Dharmacon |
Cancer Research UK |
Agreement |
Dharmacon will provide siRNA libraries to Cancer Research UK |
The libraries initially include protein kinase genes and associated pathways; terms were not disclosed (4/18) |
DNAPrint |
Beth Israel Deaconess Medical Center |
License agreement |
DNAPrint got rights to develop a new form of the anemia drug erythropoietin |
Terms of the worldwide, royalty- bearing license were not disclosed (4/5) |
Elixir |
University of California |
License agreement |
Elixir got exclusive rights to technology covering SirT1 and the HIV TAT protein |
SirT1 is a member of the sirtuin class of enzymes; Elixir already had rights from UC to SirT2 and SirT3; they may have applicability in metabolic diseases, HIV and cancer (5/19) |
Galapagos |
Cystic Fibrosis Foundation Therapeutics Inc. |
Collaboration |
Galapagos will apply its technologies to discover and validate novel drug targets for CF |
Galapagos will get €1.3M from CFFT, and has an option to further develop targets identified in the program (4/14) |
Genedata AG* |
NIH Chemical Genomics Center |
Collaboration |
Deal to integrate Genedata Screener software with the NCGC's IT infrastructure |
The center will use the software system in its high-throughput screening efforts; terms of the deal were not disclosed (5/12) |
GeneGo Inc.* |
Translational Genomics Research Institute |
License agreement |
TGen licensed GeneGo's MetaCore platform |
The platform is used for mining high- throughput experimental data; terms of the deal were not disclosed (5/16) |
Generex |
The Scripps Research Institute |
Agreement |
Scripps researchers will test the potency of a modified DNA vaccine for treating various forms of cancer |
The deal was made between Scripps and Generex subsidiary Antigen Express; terms were not disclosed (5/11) |
GenoLogics |
The Institute for Systems Biology |
Collaboration |
To increase the utility of ISB's open-source software tools in the life sciences community |
GenoLogics will work to enhance the functionality and usability of the tools, and integrate them into its ProteusLIMS platform (5/19) |
GenVault Corp.* |
University of Texas |
Agreement |
GenVault acquired full rights to DNA-labeling technology developed at the university |
The patent allows GenVault to offer and license its GenCode to a broader market; terms of the deal were not disclosed (5/11) |
Genzyme Corp. |
Massachusetts General Hospital and Dana-Farber Cancer Institute |
License agreement |
Genzyme got diagnostic rights to gene mutations recently found in some patients with non- small-cell lung cancer |
Genzyme intends to develop and market a test for EGFR markers that can be used to help identify patients most likely to respond to targeted therapies (5/2) |
Guava |
AIDS Healthcare Foundation |
Partnership |
They intend to increase access in resource- limited nations to AIDS diagnosis and treatment monitoring |
They will make Guava's EasyCD4 system for counting CD4 T cells available at five sites; the program would be expanded after establishing feasibility (4/27) |
Helix |
National Research Council of Canada |
License agreement |
Helix licensed an antibody that targets cancerous tissue in the lung |
The antibody is being combined with Helix's DOS47 drug candidate; Helix will make up-front and milestone payments (5/2) |
Ingenuity |
National Cancer Institute Center for Cancer Research |
License agreement |
The NCI licensed access to the Ingenuity Pathways Analysis software |
The technology includes millions of individually modeled relationships between proteins, genes, complexes, cells, tissues, drugs and diseases (4/12) |
Ingenuity |
Erasmus University Medical Center (the Netherlands) |
License agreement |
The center licensed access to the Ingenuity Pathways Analysis software |
They also entered a collaboration to develop new algorithms, visualizations and practical applications in molecular and clinical diagnostics (3/23) |
InNexus |
Mayo Clinic |
Collaboration |
Deal focused on creation of new antibody-based therapies |
They intend to develop products for cancer, cardiovascular disease and other conditions under the multiyear agreement (5/17) |
Juvaris Bio- |
International AIDS Vaccine Initiative |
Collaboration |
Deal to use Juvaris' immunostimulant technology to screen HIV vaccine candidates |
IAVI investigators will test the technology with HIV antigens; terms of the deal were not disclosed (3/23) |
Kane Biotech |
University of Medicine and Dentistry of New Jersey |
License agreement |
Kane got rights to all human and industrial applications of the dispersin B enzyme |
Dispersin B is an enzyme responsible for the dispersal of bacterial biofilms; terms of the deal were not disclosed (4/26) |
Large Scale |
University of Utah Research Foundation |
Collaboration |
To identify biomarkers from maternal blood tests for the early diagnosis of pregnancy- related complications and disorders |
LSBC subsidiary Predictive Diagnostics Inc. will analyze blood samples provided by UURF; terms of the deal were not disclosed (3/21) |
Macrogenics |
Washington University School of Medicine |
License agreement |
Macrogenics got rights to a monoclonal antibody against the West Nile virus |
Macrogenics participated in promising preclinical studies; terms of the license were not disclosed (4/22) |
Metabolon |
Massachusetts General Hospital |
Collaboration |
To discover biomarkers for diabetic nephropathy in Type I diabetes |
The work is being funded by a grant from the National Institute of Diabetes and Digestive and Kidney Diseases to Massachusetts General Hospital (3/29) |
Nastech |
Mayo Clinic |
Collaboration |
Mayo will evaluate Nastech's RNAi-based formulations in immune cells from patients with rheumatoid arthritis |
The collaboration will involve the measurement of a series of inflammatory cytokines for the purpose of selecting a candidate for preclinical development (4/5) |
Neoprobe |
University of California at San Diego |
Option agreement |
Neoprobe got an option to expand the field of use for Lymphoseek |
The license was expanded to allow for use of the compound as an optical or ultrasound agent; terms were not disclosed (4/20) |
NephroGenex Inc.* |
Karolinska Institute (Sweden) |
Licenseagreement |
NephroGenex acquired rights in the renal disease field to Goodpasture antigen- binding protein kinase technology |
GPBP kinase is active against extracellular matrix molecules; terms of the deal were not disclosed (5/5) |
NephroGenex |
Biomedical Research Foundation (Spain) |
License agreement |
NephroGenex acquired rights to glomerular transcriptome profiling technology |
The molecular profiling technology is used to identify renal-specific pathogenic pathways (5/5) |
Neurologix |
Keio University (Japan) |
License agreement |
Neurologix got rights outside Japan to the humanin gene |
The gene, which may prevent amyloid toxicity, will be used as an approach to treating Alzheimer's and other CNS diseases (5/18) |
OncoGenex |
University of British Columbia (Canada) |
License agreement |
OncoGenex got rights to inhibitors of heat-shock protein 27 |
The lead product, OGX-427, is expected to enter clinical development in 2006; terms were not disclosed (4/26) |
OncoMethylome |
Max Planck Society (Germany) |
License agreement |
OncoMethylome got rights to technology for silencing tumor- suppressor genes by DNA methylation |
The technology will be used for early prostate cancer detection, prognosis and monitoring of recurrence; terms were not disclosed (5/17) |
Ortec |
University of California at Berkeley |
Collaboration |
To evaluate Ortec's collagen scaffold for use in cardiovascular tissue regeneration |
The work is being done with the university's Center for Tissue Engineering; terms were not disclosed (5/19) |
ParAllele |
Baylor University |
Collaboration |
To measure the genetic basis of patient response to the flu vaccine |
They will use ParAllele's SNP genotyping panel in the effort; terms were not disclosed (4/27) |
ParAllele |
University of Southern California |
Collaboration |
To discover genes associated with lupus |
They will use ParAllele's SNP genotyping panel in the effort; terms were not disclosed (4/27) |
ParAllele |
University of Iowa |
Collaboration |
To accelerate the discovery of genes associated with age- related macular degeneration |
Iowa researchers will use the pharmacogenomics and high- throughput gene mutation discovery technologies of ParAllele in their research (3/29) |
Peregrine |
National Institute of Allergy and Infectious Diseases |
Collaboration |
The NIAID will screen Anti-Phospholipid Therapy agents, including Tarvacin |
Peregrine's compounds will be screened for activity against various enveloped viral pathogens of health and bioterrorism concern (4/4) |
PharmaStem |
University of Texas M.D. Anderson Cancer Center |
License agreement |
The cancer center licensed PharmaStem's technology for the storage and use of umbilical cord blood |
The technology is covered under five patents; PharmaStem is entitled to certain milestone payments (4/20) |
ProChon |
Musculoskeletal Transplant Foundation |
Collaboration |
To develop products combining ProChon's growth factor and cell technology with MTF's allograft and tissue materials |
The two deals include an equity investment agreement; MTF will provide R&D funding and be responsible for development and commercialization (4/10) |
Reata |
University of Texas Southwestern Medical Center and Victoria University |
License agreement |
Reata got exclusive worldwide rights to a new class of anticancer compounds |
The lead compound, peloruside A, was discovered in a marine sponge in New Zealand's Pelorus Sound; terms of the deal were not disclosed (5/10) |
Sareum Holdings |
Cancer Research Technology Ltd. (UK) |
Collaboration extension |
Sareum will provide computational chemistry services for a further six months |
The initial fee-for-service deal related to cancer discovery programs at CRT was signed in December 2004; terms were not disclosed (4/11) |
Senesco Technologies |
University of Pittsburgh |
Funded research |
The company will fund work on inflammatory bowel disease models |
The study will assess inhibition of the company's Factor 5A gene technology on IBD (5/12) |
Senesco |
University of Virginia |
Funded research |
The company will fund an in vitro bladder cancer study |
The study will assess up-regulation of the company's Factor 5A gene on bladder cells (5/12) |
Senetek plc |
Unnamed research foundation |
License extension |
Senetek got rights to diagnostic monoclonal antibodies used for research in various disease states |
The deal was extended through 2011; Senetek would pay royalties on any resulting sales (4/7) |
Serologicals |
University of California |
License agreement |
Serologicals subsidiary Upstate Group got rights to sell the anti-ZAP-70 monoclonal antibody for diagnostic uses |
Expression levels of the ZAP-70 protein have been shown to predict the aggressiveness of chronic lymphocytic leukemia; terms of the deal were not disclosed (3/28) |
Sirtris |
Washington University School of Medicine |
License agreement |
Sirtris got exclusive rights to technology related to Class III histone deacetylases |
The technology, also known as sirtuins, may have applicability in neuroprotection; terms were not disclosed (5/19) |
Stratagene |
Sidney Kimmel Cancer Center |
License agreement |
Stratagene got rights to technology on a novel methodology for discovering cancer- related genes |
Stratagene also got exclusive rights to certain gene groups that may have predictive capabilities in cancer; terms of the deal were not disclosed (4/15) |
SurModics Inc.(SRDX) |
Rutgers University |
License agreement |
SurModics got an option to acquire an exclusive license to two classes of biodegrad-able polymers |
The polymers will be used for site-specific delivery of drugs to the eye; terms of the deal were not disclosed (3/29) |
Telik Inc. |
Mount Sinai School of Medicine |
Collaboration |
Deal to discover and evaluate small molecules for new cancer targets |
They will use Telik's TRAP discovery technology in the effort; terms of the deal were not disclosed (4/22) |
Tm Bioscience |
Akron Children's Hospital |
Supply agreement |
Tm will provide Tag-It reagents to the hospital |
The hospital will use the reagents in its cystic fibrosis gene assay; terms were not disclosed (5/18) |
Tm Bioscience |
McMaster University (Canada) |
Collaboration |
To develop an upper respiratory viral panel |
They will use Tag-It technology from Tm, which would commercialize resulting products (5/9) |
TopoTarget A/S* |
National Cancer Institute |
Cooperative Research and License Agreement |
Deal to conduct preclinical studies on PXD101 to better understand its anti-tumor activity |
An additional goal will be to select the best next generation of histone deacetylase inhibitors for development (5/12) |
U.S. BioDefense |
University of Texas M.D. Anderson Cancer Center |
License agreement |
U.S. BioDefense got an option to review and license technology from the cancer center |
The technology covers the use of non-marrow stem cells for cardiac regeneration; terms of the deal were not disclosed (5/10) |
U.S. BioDefense |
University of Minnesota |
License agreement |
U.S. BioDefense got a six-month option to license a patent on hematopoietic stem cells |
The patent covers a method for selective engraftment of drug- resistant stem cells, which can be applied to gene therapy; terms were not disclosed (3/21) |
Viragen Inc. |
University of Miami |
Option termination |
Viragen chose not to license VG104, the IEP 11 peptide with applicability in cancer |
The option expired and all development activities relating to VG104 have been discontinued (5/18) |
Viragen Inc. |
Cancer Research Technology Ltd. (UK) |
License agreement |
Viragen got exclusive rights to commercialize an anti-CD55 antibody |
The antibody (VG102) is in pre- clinical development for treating a range of cancers; terms of the deal were not disclosed (5/9) |
Xenomics Inc. |
Eastern Virginia Medical School |
Research agreement |
Deal to study Xeno- mics' technology for detecting Down syndrome in unborn children |
The technology entails analysis of maternal urine samples; terms were not disclosed (5/12) |
Xenomics Inc. |
North Shore-Long Island Jewish Health System |
Research agreement |
Deal to study the use of DNA technology to detect a number of fetal genetic problems |
They intend to conduct clinical trials of the company's Trans-renal DNA product; terms were not disclosed (5/12) |
Xsira |
Harbor-UCLA Medical Center |
License agreement |
Xsira got rights to develop adenosine as an analgesic for post- operative pain |
Initial studies of adenosine in the surgical setting already have been conducted; terms of the worldwide license were not disclosed (4/14) |
| | ||||
Notes: | ||||
This chart does not include grants or contract awards, or agreements between biotech companies and clinical trial centers. | ||||
* Denotes privately held company. | ||||
@ Some institutions listed have for-profit components. They are located in the U.S. unless otherwise noted. | ||||
Unless otherwise noted, shares are traded on the Nasdaq exchange. | ||||
AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange. | ||||
